← Leaderboards
David M. Katz
Case Western Reserve University
$8,572,425
Attributed
$8,804,001
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $722K · FY2005–18$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,804,001 · 7
By mechanism
R01$6,014,488 · 3
R21$1,255,652 · 2
P01$1,137,611 · 1
R56$396,250 · 1
Top collaborators
- Nicholas K Tonks2 shared
Most similar at Case Western Reserve University
Same institution · by research overlap
- Thomas E Dick$7,172,255
- Michael F Romero$9,271,689
Others in their field
Top investigators on “Mutant”
- Kc Kent Lloyd · University Of California At Davis$103,993,616
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Bruce A Beutler · Ut Southwestern Medical Center$34,438,453
- Oscar A. Carretero · Henry Ford Health System$33,594,856
- Stuart H Orkin · Children'S Hospital Boston$33,454,343
- Tracy T Batchelor · Dana-Farber Cancer Inst$31,851,614
Research focus
MutantSynapsesBrain StemGenesRett SyndromeSignal TransductionGeneticBaseLightNeuronsResponseDesignLaboratoriesNeurotrophic Tyrosine Kinase Receptor Type 2ExhibitsMethyl-Cpg-Binding Protein 2Research StudyDefectPhenotypeIn VivoCarotid BodyLaboratory MouseMutant Strains MiceBrain
Grant awards (27)
PTP1B Inhibitors for the Treatment of Rett Syndrome$204,406
R21 · FY2018 · MH · contact PI
PTP1B Inhibitors for the Treatment of Rett Syndrome$258,746
R21 · FY2017 · MH · contact PI
Prefrontal cortical dysfunction in Rett syndrome$396,250
R56 · FY2016 · NS · contact PI
Preclinical evaluation of NMDA receptor antagonists for treating Rett Syndrome$396,250
R21 · FY2015 · NS · contact PI
Preclinical evaluation of NMDA receptor antagonists for treating Rett Syndrome$396,250
R21 · FY2014 · NS · contact PI
Respiratory Circuit Dysfunction in Rett Syndrome$476,142
R01 · FY2013 · NS · contact PI
Respiratory Circuit Dysfunction in Rett Syndrome$529,450
R01 · FY2012 · NS · contact PI
Respiratory Circuit Dysfunction in Rett Syndrome$386,867
R01 · FY2011 · NS · contact PI
BDNF AND MeCP2 in Autonomic Dysfunction$360,834
R01 · FY2010 · NS · contact PI
BDNF AND MeCP2 in Autonomic Dysfunction$364,754
R01 · FY2009 · NS · contact PI
BDNF AND MeCP2 in Autonomic Dysfunction$193,700
R01 · FY2009 · NS · contact PI
BDNF AND MeCP2 in Autonomic Dysfunction$367,735
R01 · FY2008 · NS · contact PI
Regulation of carotid body afferent development$329,612
R01 · FY2008 · HL · contact PI
BDNF AND MeCP2 in Autonomic Dysfunction$392,416
R01 · FY2007 · NS · contact PI
Regulation of carotid body afferent development$329,612
R01 · FY2007 · HL · contact PI
Regulation of carotid body afferent development$326,152
R01 · FY2006 · HL · contact PI
BDNF in plasticity of chemoafferent pathway$306,223
P01 · FY2006 · HL · contact PI
Regulation of carotid body afferent development$334,000
R01 · FY2005 · HL
BDNF in plasticity of chemoafferent pathway$297,476
P01 · FY2005 · HL
REGULATION OF CAROTID BODY AFFERENT DEVELOPMENT$298,023
R01 · FY2003 · HL
REGULATION OF CAROTID BODY AFFERENT DEVELOPMENT$289,344
R01 · FY2002 · HL
BDNF in plasticity of chemoafferent pathway$266,956
P01 · FY2002 · HL
Chemoreflex plasticity and BDNF$114,750
R01 · FY2002 · HL
Chemoreflex plasticity and BDNF$367,445
R01 · FY2001 · HL
REGULATION OF CAROTID BODY AFFERENT DEVELOPMENT$280,916
R01 · FY2001 · HL
REGULATION OF CAROTID BODY AFFERENT DEVELOPMENT$272,736
R01 · FY2000 · HL
NEURAL SUBSTRATES FOR HYPOXIC EXCITATION OF BREATHING$266,956
P01 · FY2000 · HL